XML 18 R21.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of estimated useful lives of property, plant and equipment

 

 

 

 

Production equipment

    

3 to 13 years

Office furniture and equipment

 

3 to 10 years

Buildings

 

39 years

Building improvements

 

15 years

 

Schedule of significant customers

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Three Months Ended

 

 

    

March 31, 2020

 

    

March 31, 2019

 

Number of significant customers

 

 

 3

 

 

 

 3

 

Aggregate dollar amount of net sales to significant customers

 

$

5.4 million

 

 

$

3.9 million

 

Percentage of net sales to significant customers

 

 

48.2

%

 

 

48.6

%

 

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the three months ended March 31, 2020:

 

    

 

 

    

Blood

    

 

 

    

 

 

    

Total

 

 

 

 

 

Collection

 

EasyPoint®

 

Other

 

Product

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

6,972,935

 

$

580,123

 

$

765,860

 

$

17,879

 

$

8,336,797

North and South America sales (excluding U.S.)

 

 

2,054,784

 

 

2,700

 

 

1,496

 

 

687,420

 

 

2,746,400

Other international sales

 

 

114,830

 

 

1,740

 

 

 

 

2,450

 

 

119,020

Total

 

$

9,142,549

 

$

584,563

 

$

767,356

 

$

707,749

 

$

11,202,217

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the three months ended March 31, 2019:

 

    

 

 

    

Blood

    

 

 

    

 

 

    

Total

 

 

 

 

 

Collection

 

EasyPoint®

 

Other

 

Product

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

5,625,387

 

$

451,077

 

$

48,472

 

$

14,975

 

$

6,139,911

North and South America sales (excluding U.S.)

 

 

1,330,330

 

 

3,863

 

 

252

 

 

925

 

 

1,335,370

Other international sales

 

 

241,243

 

 

210,700

 

 

 

 

5,250

 

 

457,193

Total

 

$

7,196,960

 

$

665,640

 

$

48,724

 

$

21,150

 

$

7,932,474

 

Schedule of earnings per share

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Three Months Ended

 

    

March 31, 2020

    

March 31, 2019

Net income (loss)

 

$

322,773

 

$

(129,221)

Preferred stock dividend requirements

 

 

(174,143)

 

 

(176,249)

Income (loss) applicable to common shareholders

 

$

148,630

 

$

(305,470)

Weighted average common shares outstanding

 

 

32,681,204

 

 

32,666,454

Weighted average common and common equivalent shares outstanding — assuming dilution

 

 

32,745,972

 

 

32,666,454

Basic earnings (loss) per share

 

$

0.00

 

$

(0.01)

Diluted earnings (loss) per share

 

$

0.00

 

$

(0.01)